But drugmakers have argued this could suck supplies out of Greece if Athens leaves the euro and prices in euro terms fall sharply. The European Association of Euro Pharmaceutical Companies, representing firms involved in this so-called parallel trade, said drugmakers were wrong to say supplies could be in jeopardy if Europe did not take such emergency...» Read More
Hey folks--we have guest blogger Jeff Mishlove's contest picks for the day. Let's get right to his comments: Now that the Tuesday results are in, I see that my top recommendation for Monday had a significant price gain. That was Adtran, Inc., which rose 6.16%. This stock had a lot going for it: it was favored by hedge funds and professional investors; it was approaching its 52-week high; a significant amount of stock was controlled by short sellers..
Fast-selling cancer drugs boosted first-quarter sales at Roche Holding by 16% to 11.4 billion Swiss francs ($9.41 billion), the Swiss drugmaker said, raising its outlook for the full year.
Should the government be allowed to negotiate Medicare drug prices? Two health-policy experts joined "Power Lunch" to debate whether Federal influence will damage the free market -- or if the current ban on government negotiations hurts the consumer more.
Merck and GlaxoSmithKline both released news about their respective treatments for human papillomavirus Tuesday, leaving them "duking it out over what's expected to be the multi-billion dollar HPV cervical cancer vaccine market," reported CNBC's Mike Huckman.
Johnson & Johnson beat the Street and raised its outlook for this year, but the hybrid Pharma/Consumer Products/Medical Devices company posted a much bigger drop in sales of its highly profitable drug-coated stents than analysts expected. Stents are the expensive, little wire mesh tubes that prop open clogged arteries. Recently, sales of stents coated with drugs have come under increasing scrutiny over safety.
Blogger Timothy Sykes is back with his contest picks. Here's his post: I hope everyone tuned in Friday to witness me becoming the first guest to bring female models on CNBC to show off the beauty of stock charts. The audience and the other studio guests loved it so hopefully I’ve started a new trend. We’ll see…This week’s picks are (in order of importance)...
Healthcare giant Johnson & Johnson reported quarterly earnings above Wall Street estimates and raised 2007 earnings guidance, sending shares up almost 3%.
We have more video from Friday night's contest program, "How To Win." Specifically, more stock picks from our guest analysts. One of them, Timothy Sykes, who is also a guest blogger, loves the charts as you'll hear him explain. He also explains, his picks could have an upside, as well as a down side. So it's buyer beware for sure (fyi--it's that way with all the picks!).
Pharmaceutical maker Shire said Monday that its shareholders approved the proposed acquisition of New River Pharmaceuticals.
Drug maker Eli Lilly reported first-quarter earnings and sales ahead of market expectations Monday and also boosted guidance for the year, thanks to strong sales of drugs for schizophrenia and depression.
Here's our look at contest stocks from Thursday's close to Friday's close. Old stand by Freemont General brought owners/sellers some new gains. The most active and widely held stocks remained pretty much the same as they have been. One of the best performers Cott, was up on consolidation news involving Cadbury. Here's the breakdown:
John Lechleiter President and Chief Operating Officer of Eli Lilly, told CNBC’s “Squawk Box” that sales of Zyprexa, a drug used to treat schizophrenia, are strong. “We continue to be very bullish about Zyprexa,” Lechleiter said Monday. “We saw 6% sales growth in the U.S. this quarter. We had 14% sales growth internationally.”
It’s Friday, and that means it’s time to huddle up for Cramer’s plays for next week. Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
Lucky Friday the 13th: As I’ve often detailed, there are many moving parts to getting breaking news on the air. "Friday the 13th" is the last day one might think the stars would decide to align to our benefit, but they did. Beverage maker Cott had been the subject of speculation all day, focusing on a possible merger with Cadbury Schweppes. It was halted before the New York Stock Exchange open for “news pending,” which, of course, only served to fuel that speculation. ...
Superstition be darned. Shares of Dow component Merck are trading above $50 intra-day. That's the first time they've crossed 50 since October 9, 2003--nearly one year before the company pulled Vioxx off the market. So, what's going on?
The maker of the FluMist vaccine said it was putting istself up for sale, causing its shares to surge more than 10%. MedImmune also said that certain major drugmakers had already indicated they might be interested in a takeover.
Merck shares rose sharply Friday after the drugmaker raised its outlook for first-quarter and full-year earnings, citing strong sales across its range of products, and said a federal court judge dismissed a class-action securities lawsuit against the company.
Inflation data could play a big role in setting the course for stocks, which so far are looking for direction ahead of the opening. Asia markets were mostly lower, while Europe's stock markets this morning are mostly higher.
Nobody stays best of breed forever. And no matter how you feel about a company's reputation, only the fundamentals matter at end of day. For that reason, you should never hesitate to clear a poor performer from your portfolio - no matter how much of a blue chip you think it is.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
Merck's new pain reliever drug Arcoxia, which was proposed as a successor to Vioxx, was rejected by a federal health advisory panel. A Food and Drug Administration drug safety expert earlier told the panel that the drug may increase substantially the risk of stroke and heart attack and is no more effective for pain relief than other medicines in the same class.